In the last decade, the field of aging biology has expanded around two central concepts: mitochondrial dysfunction and zombie cells (senescent cells). For years, both were considered separate items on the 'hallmarks of aging' list. Now, accumulating evidence shows something entirely different: these two processes are, in fact, one. A senescent cell is not just a cell that has stopped dividing. It is a cell with broken mitochondria at its core, and these broken mitochondria are the engine that produces all its destructive effects on the surrounding tissue.
A review published in Technology Networks on May 15, 2026, titled Targeting Mitochondrial Pathways To Reverse Cellular Senescence summarizes the therapeutic approaches active in 2026 that attempt to break this link. The idea is simple but powerful: if damaged mitochondria are the source of senescence, then repairing mitochondria can either restore the cell to normal function or at least eliminate the cell before it causes further damage. In this article, we will review the specific pathways targeted in 2026 and the drugs leading the front.
What is a Senescent Cell with Broken Mitochondria
A senescent cell is a cell that has irreversibly stopped the cell cycle but has not died. Instead, it remains in the tissue and secretes a cocktail of inflammatory molecules known as SASP (Senescence-Associated Secretory Phenotype). The problem: SASP infects healthy cells in the environment, causes chronic inflammation, and accelerates the aging of entire tissues.
The mitochondrial signature of a senescent cell has recently been recognized as a key component of this state:
- Low mitochondrial membrane potential (Δψm), the mitochondria cannot maintain the electrical charge essential for ATP production.
- Fragmented mitochondrial network, instead of a connected and dynamic mitochondrial network, the cell contains small, isolated mitochondria.
- Increased reactive oxygen species (ROS) leakage, the electron transport chain 'leaks' electrons that produce high amounts of superoxides.
- Impaired mitophagy, the cell fails to get rid of damaged mitochondria.
- cGAS-STING activation, mitochondrial DNA leaking into the cytoplasm activates this DNA sensor, fueling the inflammatory SASP.
This mitochondrial collapse is not a result of senescence. It is a cause of senescence. Studies from 2020 onward have shown that injecting normal mitochondria into senescent cells can partially restore their function. And conversely, damaging mitochondrial DNA in a young cell can cause it to become senescent. The connection is bidirectional.
The Connection Between Mitochondria and Senescence: Key Pathways
The practical question of 2026 is: which mitochondrial pathway should be targeted to treat senescent cells? There are at least five leading pathways, each with a drug or supplement attempting to activate it.
1. Restoring membrane potential. If the problem is low Δψm, one can try to restore it. Molecules like SS-31 (elamipretide, once called Bendavia) bind to cardiolipin in the inner mitochondrial membrane and improve its efficiency. A phase 2 trial in elderly individuals with muscle weakness showed significant metabolic improvement.
2. Neutralizing ROS at the source. Most antioxidants (vitamin C, vitamin E) do not reach the mitochondria at all. But MitoQ, a derivative of CoQ10 engineered with a triphenylphosphonium cation (TPP+), is drawn directly into the mitochondria thanks to the membrane potential. There, it neutralizes superoxides at the site of their formation, before they can damage mtDNA.
3. Enhancing mitophagy. Urolithin A is a metabolite that our microbiome produces from ellagitannins (compounds found in pomegranates and walnuts). It activates specific mitophagy via the PINK1-Parkin pathway. In senescent cells, it can 'take out the mitochondrial trash' and improve function.
4. New mitochondrial biogenesis. If existing mitochondria are too broken, perhaps the solution is to produce new ones. PGC-1α is the master regulator of this biogenesis. Exercise, especially HIIT, is the most powerful natural stimulator of PGC-1α. Drugs attempting to mimic this effect (ZLN005, SR-18292) are still in early research stages.
5. Pushing to apoptosis. Sometimes a senescent cell is too broken to save. In such a case, the goal is to kill it. This is where senolytics come in. Drugs like navitoclax, fisetin, and dasatinib + quercetin act mitochondrially: they lower the threshold for apoptosis in cells whose mitochondria are already on the edge, causing only them (not healthy cells) to die.
Current Evidence
Study 1: MitoQ in Senescent Cells, Newcastle University 2024
A British team showed that MitoQ reduced the number of senescent cells by 46% in the skin of aged mice after 8 weeks of administration in drinking water. Additionally, SASP levels, measured by IL-6 and MMP-3, dropped by about 30%. This showed that not only were there fewer senescent cells, but those that remained were 'less toxic' to the environment.
Study 2: Urolithin A in the Elderly, Mitopure (Amazentis), 2022-2025
A multi-center trial on 88 elderly individuals taking 500-1000 mg of urolithin A daily for 4 months showed a 12% improvement in leg muscle strength and a 17% increase in aerobic endurance. Biopsy tests showed a decrease in the number of senescent muscle cells in the treatment group. The trial, published in JAMA Network Open, was the first human proof of a link between improved mitophagy and reduced senescent burden.
Study 3: SS-31 (elamipretide), Stealth BioTherapeutics, 2025
A phase 2 study on 168 people over 65 with frailty syndrome showed a 22% improvement in 6-minute walk distance after 12 weeks of daily injections. The peptide works by stabilizing cardiolipin in the inner mitochondrial membrane. A decrease in blood senescence markers indicated that not only did the muscle strengthen, but it also 'rejuvenated' biologically.
Study 4: NMN and Senescence, Cancer Warning, Washington University 2024
NMN raises NAD+ by 30-40%, which improves mitochondrial function and reduces senescence in preclinical models. However, a study in Cancer Cell from 2024 showed that resistant cancer cells use additional NAD+ to survive treatment. Despite the anti-senescence potential, NMN use should be considered cautiously in individuals with cancer risk factors.
Study 5: HIIT and Senescent Cell Clearance, Mayo Clinic 2025
After 12 weeks of HIIT, elderly individuals aged 65-80 showed a 31% reduction in the number of senescent cells in muscle, along with a 69% increase in mitochondrial gene expression. In other words, exercise worked both as a biogenesis stimulator and as a natural senolytic. No drug achieves this combination.
What About Neurodegenerative and Cardiovascular Diseases?
The mitochondrial collapse in senescent cells is particularly relevant to diseases where brain and heart cells are damaged. In Parkinson's disease, dopaminergic neurons with damaged mitochondria become senescent and release SASP that infects neighboring neurons. A phase 1 trial with MitoQ in Parkinson's disease began in 2025 and is expected to yield preliminary results in 2027.
In Alzheimer's disease, brain ATP levels drop years before symptom onset. The team at the University of Queensland showed that urolithin A reduced senescence in microglia (the brain's immune cells) in a mouse model of Alzheimer's, which also reduced beta-amyloid load. The corresponding clinical trial is in phase 2.
Also in heart failure, the heart muscle contains many mitochondria per cell. When they break down with age, some cardiomyocytes become senescent and contribute to failure. A combination of SS-31 and senolytics is in a trial for failing hearts in the elderly, with encouraging preliminary results.
Should We Start Taking Mitochondrial Supplements?
Each supplement has its profile and rationale:
Urolithin A (500 mg per day)
The best clinical evidence. Price: 350-500 shekels per month. Particularly reasonable for elderly individuals with muscle weakness or sarcopenia. Risk: no safety data beyond one year yet.
MitoQ (10-20 mg per day)
Less proven in humans but with a unique profile due to its mitochondrial targeting. Price: around 250-300 shekels per month. Warning: an antioxidant of excessive strength may disrupt normal ROS signaling, which itself mediates adaptation to exercise. It is advisable not to take it within 2 hours of a workout.
NMN/NR
Available everywhere but with the cancer caveat. If you are over 60 or have a family history of cancer, consult a doctor before starting.
CoQ10 (100-200 mg per day)
The veteran and cheap option. Most of the supplement does not penetrate the mitochondria (hence MitoQ was developed), but it still has a role in people taking statins that lower internal CoQ10.
Senolytics (fisetin, dasatinib + quercetin)
Fisetin is sold as a dietary supplement at a dose of 500-1000 mg for two days per month (pulses). Human evidence is still thin, but the safety profile is good. Dasatinib is a cancer drug and can only be prescribed by a doctor.
What to Do Starting Today
- Add 2-3 HIIT sessions per week. 4 rounds of 4 minutes at high intensity, with 3 minutes of rest. This is the most proven method in humans to improve mitochondrial biogenesis and eliminate senescent cells simultaneously.
- Fast for 14-16 hours daily. Activates mitophagy via AMPK and mTOR, and raises NAD+ without supplements. This is a 'natural' approach to the effect urolithin A tries to mimic.
- Pomegranates, walnuts, raspberries, three times a week. Provide ellagitannins that the microbiome will convert to urolithin A. In 60% of the population, the conversion is efficient. For the rest, direct supplementation is better.
- Brief cold exposure, a cold shower for 2-3 minutes at the end of your shower. Activates UCP1 and improves mitochondrial activity.
- Quality sleep of 7-8 hours. During deep sleep, mitophagy reaches its peak activity. Poor sleep is equivalent to stopping the natural mechanism for clearing damaged mitochondria.
- Consider pulses of fisetin once a month, 500 mg per day for two days, if you are over 50. The evidence is modest but the risk is low.
The Broader Perspective
The story of mitochondria and senescence is an example of how the biology of aging is maturing. For twenty years, researchers treated 'mitochondrial function' and 'senescence' as two separate topics, with two separate types of drugs. Now it is clear: These are not two separate hallmarks. It is the same process from two different angles.
The practical implication is important. A drug that works on mitochondria (like MitoQ or urolithin A) can be a de facto senolytic, because it either restores senescent cells to function or pushes them to apoptosis. And conversely, senolytics (like fisetin or dasatinib) work through the mitochondria: they lower the threshold for apoptosis in cells whose mitochondria are already broken.
But the most important conclusion is humility. No drug has proven to extend lifespan in humans. The intervention with the strongest evidence remains the one without a patent: regular exercise, quality sleep, and occasional fasting. These activate the same mitochondrial pathways that scientists are trying to mimic with molecules, only in a balanced way and without side effects. Until research matures into a real drug, the answer to zombie cells lies in running shoes and on the plate.
References:
Technology Networks - Targeting Mitochondrial Pathways To Reverse Cellular Senescence (2026)
💬 תגובות (0)
היו הראשונים להגיב על המאמר.